Approval was primarily based on the results of the CodeBreaK 100 study, a multicenter, single-arm, open-label clinical trial that enrolled patients with locally advanced or metastatic KRAS G12C-mutated NSCLC who had progressed on or after prior systemic treatments [47]. Here, KRAS is linked to non-small cell lung carcinoma.